IPI-145 Single Ascending, Multiple Ascending, Food Effect and Drug-Drug-Interaction Study
This study has been completed.
Information provided by (Responsible Party):
Infinity Pharmaceuticals, Inc.
First received: February 10, 2012
Last updated: March 6, 2012
Last verified: March 2012
The purpose of this study is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of IPI-145 after single and repeat oral administration, and to evaluate the effects of food and ketoconazole on the plasma pharmacokinetics of IPI-145.
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Basic Science
||A Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and the Effect of Food and Ketoconazole on the Pharmacokinetics of IPI-145 When Administered to Healthy Adult Subjects
Primary Outcome Measures:
- Safety and tolerability assessments consisting of adverse events, vital signs, 12-lead ECG, clinical laboratory tests and physical examinations will be performed following IPI-145 single and repeat oral administration in healthy subjects [ Time Frame: 8 months ] [ Designated as safety issue: Yes ]
- Plasma concentrations of IPI-145 and metabolites [ Time Frame: 8 months ] [ Designated as safety issue: Yes ]
| Study Start Date:
| Study Completion Date:
| Primary Completion Date:
||February 2012 (Final data collection date for primary outcome measure)
Single ascending dose up to 6 cohorts; multiple ascending dose up to 4 cohorts; food effect arm; ketoconazole drug interaction study
Placebo Comparator: Placebo
Single ascending dose up to 6 cohorts; multiple ascending dose up to 4 cohorts; food effect arm
|Ages Eligible for Study:
||18 Years to 55 Years
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
- Gender : male or female
- Age : 18-55 years, inclusive
- Body Mass Index (BMI) : 18.0-30.0 kg/m2
- Medical history without major pathology
- For males only: Willingness to use adequate contraception from the time of dosing and not donate sperm until 3 months after the follow-up visit
- Females who have a negative pregnancy test at screening and on each admission, and are of non-childbearing potential. Females of non-childbearing potential are defined as women who are surgically sterile or post-menopausal (defined as at least 1 year post cessation of menses and follicular stimulating hormone (FSH) >23.0 mIU/mL)
- Willing and able to sign the written Informed Consent Form (ICF)
- Previous participation in the current study
- Evidence of clinically relevant pathology
- History of relevant drug and/or food allergies
- Part 4 only: Known or suspected adverse reaction or contraindication to the imidazole class of drugs
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01549106
|Zuidlaren, Netherlands, 9470 AE |
Infinity Pharmaceuticals, Inc.
No publications provided
||Infinity Pharmaceuticals, Inc.
History of Changes
|Other Study ID Numbers:
|Study First Received:
||February 10, 2012
||March 6, 2012
||Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on July 24, 2014
14-alpha Demethylase Inhibitors
Molecular Mechanisms of Pharmacological Action